BEAM THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.38 USD | -1.02% |
|
-10.54% | -21.45% |
| Apr. 04 | Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing | MT |
| Apr. 04 | Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,611 | 5,327 | 2,692 | 2,159 | 1,697 | - | - |
| Enterprise Value (EV) 1 | 4,318 | 4,367 | 1,613 | 969.4 | 927.1 | 1,339 | 1,697 |
| P/E ratio | -19.5 x | -13.8 x | -9.47 x | -15.8 x | -3.93 x | -4.2 x | -3.91 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 192,105 x | 103 x | 44.2 x | 5.72 x | 26.8 x | 26.4 x | 29.5 x |
| EV / Revenue | 179,928 x | 84.2 x | 26.5 x | 2.57 x | 14.6 x | 20.8 x | 29.5 x |
| EV / EBITDA | - | -11.3 x | -4.97 x | -6.2 x | -2.15 x | -2.99 x | -3.58 x |
| EV / FCF | -38.5 x | -38.6 x | -61.1 x | -5.3 x | -2.53 x | -3.59 x | -5.09 x |
| FCF Yield | -2.6% | -2.59% | -1.64% | -18.9% | -39.5% | -27.9% | -19.6% |
| Price to Book | 15.5 x | 6.19 x | 3.66 x | 2.14 x | 2 x | 2.55 x | - |
| Nbr of stocks (in thousands) | 56,474 | 66,849 | 68,821 | 79,326 | 79,383 | - | - |
| Reference price 2 | 81.64 | 79.69 | 39.11 | 27.22 | 21.38 | 21.38 | 21.38 |
| Announcement Date | 3/15/21 | 2/28/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.018 | 0.024 | 51.84 | 60.92 | 377.7 | 63.42 | 64.3 | 57.46 |
| EBITDA 1 | - | - | -385 | -324.3 | -156.5 | -431.5 | -448.4 | -474 |
| EBIT 1 | -75.15 | -132.8 | -392.5 | -338.5 | -176.5 | -465.5 | -459.2 | -493 |
| Operating Margin | -417,522.22% | -553,166.67% | -757.01% | -555.61% | -46.73% | -734.02% | -714.15% | -858.1% |
| Earnings before Tax (EBT) 1 | -78.33 | -194.6 | -370.6 | -260.2 | -131.2 | -456.8 | -447.3 | -509 |
| Net income 1 | -91.04 | -195.9 | -370.6 | -289.1 | -132.5 | -452.3 | -446.7 | -491.5 |
| Net margin | -505,777.78% | -816,120.83% | -714.91% | -474.54% | -35.09% | -713.22% | -694.82% | -855.45% |
| EPS 2 | -2.489 | -4.190 | -5.770 | -4.130 | -1.720 | -5.442 | -5.094 | -5.466 |
| Free Cash Flow 1 | -84.52 | -112.1 | -113.1 | -26.42 | -182.9 | -366.5 | -373.5 | -333.3 |
| FCF margin | -469,561.11% | -467,075% | -218.11% | -43.37% | -48.43% | -577.89% | -580.91% | -580.16% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/15/21 | 2/28/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.763 | 51.07 | 8.432 | 16.65 | 15.8 | 20.04 | 24.21 | 20.12 | 17.19 | 316.2 | 14.66 | 14.72 | 14.77 | 14.83 | - |
| EBITDA 1 | - | -60.85 | -72.91 | - | -87.83 | -85.04 | - | -97.33 | -103.1 | 138.2 | -109.5 | -110.2 | -111 | -111.8 | - |
| EBIT 1 | -69.63 | -63.48 | -76.22 | -81.97 | -91.3 | -88.98 | -98.93 | -102.1 | -108.3 | 132.9 | -124.3 | -123.5 | -121.6 | -124.6 | -115 |
| Operating Margin | -9,126.34% | -124.31% | -904% | -492.23% | -577.9% | -444.1% | -408.66% | -507.79% | -629.72% | 42.02% | -847.85% | -839.35% | -823.06% | -840.32% | - |
| Earnings before Tax (EBT) 1 | -28.12 | -64.71 | -69.21 | -71.95 | -81.66 | -37.35 | -96.46 | -82.78 | -96.09 | 144.2 | -120.8 | -117 | -117.1 | -121.2 | -114 |
| Net income 1 | -28.12 | -64.71 | -69.21 | -71.95 | -109.6 | -38.35 | -96.46 | -82.78 | -96.09 | 142.8 | -119.3 | -115.3 | -115.4 | -118.6 | -114 |
| Net margin | -3,685.19% | -126.71% | -820.85% | -432.08% | -693.56% | -191.39% | -398.46% | -411.49% | -558.88% | 45.16% | -813.29% | -783.65% | -781.24% | -800.16% | - |
| EPS 2 | -0.4200 | -0.9500 | -1.010 | -1.020 | -1.560 | -0.5400 | -1.330 | -1.080 | -1.220 | 1.730 | -1.436 | -1.390 | -1.378 | -1.397 | -1.350 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/28/22 | 5/9/22 | 8/9/22 | 11/7/22 | 2/28/23 | 5/10/23 | 8/8/23 | 11/8/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 292 | 960 | 1,078 | 1,190 | 770 | 358 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -84.5 | -112 | -113 | -26.4 | -183 | -366 | -374 | -333 |
| ROE (net income / shareholders' equity) | - | -881% | -69.1% | -37.1% | -15.5% | -55.2% | -80.5% | -105% |
| ROA (Net income/ Total Assets) | -56.4% | -64.5% | -38.5% | -20.5% | -11.7% | -33.5% | -38.1% | - |
| Assets 1 | 161.6 | 303.9 | 963.1 | 1,408 | 1,134 | 1,350 | 1,173 | - |
| Book Value Per Share 2 | -3.920 | 5.250 | 12.90 | 10.70 | 12.70 | 10.70 | 8.400 | - |
| Cash Flow per Share 2 | - | - | -1.030 | 0.3200 | -1.930 | -4.100 | -3.840 | - |
| Capex 1 | 12.5 | 16.4 | 46.8 | 49 | 33.7 | 30.1 | 31.2 | 30.7 |
| Capex / Sales | 69,544.44% | 68,154.17% | 90.29% | 80.35% | 8.93% | 47.46% | 48.53% | 53.38% |
| Announcement Date | 3/30/20 | 3/15/21 | 2/28/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
21.38
USD
Average target price
49.54
USD
Spread / Average Target
+131.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.45% | 1.7B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BEAM Stock
- Financials Beam Therapeutics Inc.
